Top 10 Pharmaceutical Company Selects Drug Model Explorer to Support Model-Based Product Profile Visualization Pharsight Corporation, a leading provider of software and strategic services for optimizing clinical drug development, today announced that a Top 10 global pharmaceutical company has become a customer for its Drug Model Explorer (DMX) software. The DMX license agreement is the eighth Pharsight has closed with leading pharmaceutical and biotechnology companies in Europe, Japan and the United States, and is the third consecutive agreement reached with a Top10 customer in the last six months. DMX is a software tool that allows clinical drug development teams to quickly and efficiently explore the modeled efficacy, safety, and other performance attributes of a new drug versus competing therapies. "DMX provides drug development teams with a simple and flexible method to navigate model-based results and compare competitive product profiles so that they can make strategic decisions quickly and more effectively," said Shawn O'Connor, president, chief executive officer and chairman of Pharsight. "We continue to see leading pharmaceutical companies incorporate integrated drug- disease modeling, as advocated by the Food and Drug Administration in its Critical Path Initiative, into their decision-making processes. Pharsight is pleased that another top pharmaceutical company has elected to use DMX to support quantitative decision-making for promising therapies in their pipeline."